Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
Go back to Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026| Nuvel Holdings, Inc. (NASDAQ: NUVL) | Delayed: 123.73 +0.13 (0.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $123.60 | 52 Week High | $0.40 | |||
| Open | $123.57 | 52 Week Low | $0.14 | |||
| Day High | $123.80 | P/E | N/A | |||
| Day Low | $123.57 | EPS | $-0.56 | |||
| Volume | 1,297,596 | |||||
